Agios spotlights promising data for IDH1 drug, putting it on the path to FDA submission
Agios today played a few of the cards it plans to show the FDA later this year when it files for an approval of its …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
